Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2021 Oct;12(19):2622-2627.
doi: 10.1111/1759-7714.14143. Epub 2021 Sep 9.

Next-generation sequencing assisted diagnosis of cervical metastasis in EGFR-mutated lung adenocarcinoma: A case report

Li Xu  1 , Kang Li  1 , Xiaoyan Chen  2 , Bolin Chen  1 , Jia Li  1 , Lin Wu  1
Affiliations
Case Reports

Next-generation sequencing assisted diagnosis of cervical metastasis in EGFR-mutated lung adenocarcinoma: A case report

Li Xu et al. Thorac Cancer. 2021 Oct.

Abstract

EGFR mutation has been detected in more than half of non-small cell lung cancer (NSCLC) patients in Asia. Lung cancer is the main cause of malignant tumor-related death worldwide. Although distant metastases often occurs in patients with advanced NSCLC, uterine cervical metastasis is rare. Here, we report a case of EGFR-mutated lung adenocarcinoma with cervical metastasis. A 63-year-old female with known lung adenocarcinoma was found to have abnormal vaginal bleeding during osimertinib follow-up visits. Immunohistochemical (IHC) staining and next-generation sequencing (NGS) of the biopsy sample from the uterine cervical tumor confirmed metastatic dissemination from the primary lung malignancy. NGS assisted the diagnosis of uterine cervical metastasis from the primary lung. This is another major clinical application of NGS in addition to medication guidance and identification of drug resistance mechanisms.

Keywords: EGFR mutation; metastasis; next-generation sequencing; non-small cell lung cancer; uterine cervix.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflict of interest.

Figures

FIGURE 1
FIGURE 1
(a) and (b) Imaging before and after gefitinib treatment (a) on March 5, 2016, and (b) April 23, 2016. (c) and (d) Imaging before and after treatment with osimertinib (c) on March 22, 2018 and (d) on June 25, 2018. (e) Chest computed tomography (CT) scan on March 22, 2020. (f) Pelvic scan on April 26, 2020
FIGURE 2
FIGURE 2
Hematoxylin‐eosin (HE) and immunohistochemical staining (×200). (a) HE staining of the biopsy sample from the right supraclavicular node, poorly differentiated adenocarcinoma. (b) and (c) Immunohistochemical staining of (b) thyroid transcription factor‐1 (TTF‐1) and (c) cytokeratin 7 (CK7) with the right supraclavicular node biopsy sample. (d) HE staining of the biopsy sample from the cervical tumor, poorly differentiated adenocarcinoma. (e and f) Immunohistochemical staining of (e) TTF‐1 and (f) CK7 with the cervical tumor biopsy sample
See this image and copyright information in PMC

References

    1. Goljan EF. Rapid review pathology. 2nd ed.St. Louis, MO: Mosby; 2006.p. 321–4.
    1. Mollet TW, Garcia CA, Koester G. Skin metastases from lung cancer. Dermatol Online J. 2009;15:1. - PubMed
    1. Mazur MT, Hsueh S, Gersell DJ. Metastases to the female genital tract: analysis of 325 cases. Cancer. 1984;53:1978–84. 10.1002/1097-0142(19840501)53:9<1978::aid-cncr2820530929>3.0.co;2-1 - DOI - PubMed
    1. Xu Y, Liu H, Chen J, Zhou Q. Acquired resistance of lung adenocarcinoma to EGFR‐tyrosine kinaseinhibitors gefitinib and erlotinib. Cancer Biol Ther. 2010;9:572–82. 10.4161/cbt.9.8.11881 - DOI - PubMed
    1. Lam DC, Tam TC, Lau KM, et al. Plasma EGFR mutation detection associated with survival outcomes in advanced‐stage lung cancer. Clin Lung Cancer. 2015;16:507–13. 10.1016/j.cllc.2015.06.003 - DOI - PubMed

Publication types

MeSH terms